Radium-223(Ra-223) safety and efficacy in prostate cancer with bone metastases: phase 3 ALSYMPCA study findings stratified by age

被引：0
|
作者：
Sartor, Oliver [1 ]
Coleman, Robert [2 ]
Nilsson, Sten [3 ]
Heinrich, Daniel [4 ]
Staudacher, Karin
Garcia-Vargas, Jose
Vogelzang, Nicholas [5 ]
机构：
[1] Tulane Univ, Ctr Canc, New Orleans, LA 70118 USA
[2] Weston Pk Hosp, Sheffield, S Yorkshire, England
[3] Karolinska Univ Hosp, Stockholm, Sweden
[4] Akershus Univ Hosp, Nordbyhagen, Norway
[5] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
来源：
BJU INTERNATIONAL | 2013年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：15 / 16
页数：2
相关论文
共 50 条
  • [31] Radium-223 dichloride (Ra-223) hematologic and 1.5-year posttreatment safety in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from ALSYMPCA
    Conti, Peter
    Michalski, Jeff
    Skjorestad, Irene
    Wahba, Mona
    Nilsson, Sten
    JOURNAL OF NUCLEAR MEDICINE, 2014, 55
  • [32] Long-term safety and real world clinical experience of radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the phase 3 ALSYMPCA study
    Franzen, L.
    Sartor, O.
    Parker, C.
    Garcia-Vargas, J.
    Nilsson, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S271 - S271
  • [33] 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) and bone metastases from the phase 3 ALSYMPCA study
    Nilsson, Sten
    Vogelzang, Nicholas J.
    Sartor, A. Oliver
    Bottomley, David
    Coleman, Robert E.
    Skjorestad, Irene
    Wahba, Mona
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [34] Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): A phase I Prostate Cancer Clinical Trials Consortium Study
    Morris, Michael J.
    Hammers, Hans J.
    Sweeney, Christopher
    Antonarakis, Emmanuel S.
    Cho, Steve Y.
    Pandit-Taskar, Neeta
    Jacene, Heather
    Bloma, Marianne
    Aksnes, Anne-Kirsti
    O'Bryan-Tear, C. Gillies
    Carrasquillo, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] External Beam Radiation Therapy (EBRT) Use and Safety With Radium-223 Dichloride (Ra-223) in Patients With Castration-Resistant Prostate Cancer (CRPC) and Symptomatic Bone Metastases (mets) From the ALSYMPCA Trial
    Finkelstein, S. E.
    Michalski, J. M.
    O'Sullivan, J.
    Parker, C.
    Garcia-Vargas, J.
    Sartor, O.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S201 - S201
  • [36] Effect of radium-223 dichloride (Ra-223) on risk for and duration of hospitalization in ALSYMPCA by docetaxel (D) subgroup.
    Cislo, Paul
    Reuning-Scherer, Jonathan D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [37] 1.5-year post-treatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study.
    Parker, Chris
    Vogelzang, Nicholas J.
    Sartor, A. Oliver
    Bottomley, David
    Coleman, Robert E.
    Skjorestad, Irene
    Wahba, Mona
    Nilsson, Sten
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] UPDATED SURVIVAL, QUALITY OF LIFE (QOL), AND SAFETY DATA OF RADIUM-223 CHLORIDE (RA-223) IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES FROM THE PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTINATIONAL STUDY (ALSYMPCA)
    Parker, C.
    Coleman, R. E.
    Nilsson, S.
    Vogelzang, N.
    Lloyd, A. J.
    Staudacher, K.
    van Gool, R.
    Sartor, A. O.
    ANNALS OF ONCOLOGY, 2012, 23 : 296 - 296
  • [39] Updated survivl, Qulity of life (QOL), and safety Dta of Radium-223 Chloride (Ra-223) in patients with Castration-resistant Prostate Cancer (CRPC) with Bone Metastases from the phase 3 double-blind, randomized, multinational study (ALSYMPCA)
    Steuber, T.
    Parker, C.
    Coleman, R. E.
    Nilsson, S.
    Volgelzang, N.
    Lloyd, A. J.
    Staudacher, K.
    van Gool, R.
    Sartor, A. O.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 60 - 60
  • [40] Fracture risk after radium-223 (Ra-223) in metastatic castration resistant prostate cancer (mCRPC).
    Alonzi, Roberto
    Parker, Chris C.
    Tunariu, Nina
    Koh, Dow-Mu
    Staffurth, John
    Blackledge, Matthew D.
    Padhani, Anwar R.
    Tree, Alison
    Stidwill, Helen
    Finch, Jessica
    Chatfield, Peter
    Perry, Sophie
    Tovey, Holly
    Hall, Emma
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345